Showing 1591-1600 of 1644 results for "".
- Sensory Deficits Increase Risk of Dementia for Older Adultshttps://practicalneurology.com/news/sensory-deficits-increase-risk-of-dementia-for-older-adults/2468956/New research suggests that sensory deficits may be associated with an increased risk of developing both all-cause dementia and Alzheimer’s disease (AD) dementia. In a study from the University of Washington School of Public Health, 2,827 individuals, age 75 or more, who had
- First Participant Enrolled in Study of ENT-01 for Parkinson's Disease Dementiahttps://practicalneurology.com/news/first-participant-enrolled-in-study-of-ent-01-for-parkinsons-disease-dementia/2468938/The first participant is enrolled in a clinical study of ENT-01(Enterin, Philadelphia, PA), a compound designed to reverse neurologic symptoms associated with Parkinson’s disease dementia (PDD). The aim of the DEMET study, an open-label multi-center trial, is to enroll 30 participants with
- Schedule IV Designation For Solriamfetol, a New Treatment for Excessive Daytime Sleepiness in Narcolepsy or OSAhttps://practicalneurology.com/news/schedule-iv-designation-for-solriamfetol-a-new-treatment-for-excessive-daytime-sleepiness-in-narcolepsy-or-osa/2468931/The Drug Enforcement Agency DEA has designated solriamfetol (Sunosi; Jazz Pharmaceuticals, Philadelphia, PA) a schedule IV agent, meaning that it has low potential for abuse or dependence. Solriamfetol was approved for treatment of excessive daytime sleepiness associated with narcolepsy or obstru
- Minimally Invasive Removal of Deep Subcortical Hemorrhagehttps://practicalneurology.com/news/minimally-invasive-removal-of-deep-subcortical-hemorrhage/2468770/Minimally invasive techniques have been used to treat deep subcortical hemorrhages successfully. In 2 abstracts, presented at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Diego, CA, minimally invasive parafascicular surgery (MIPS) with tubular retracto
- FDA Approves Solriamfetol for Treatment of Excessive Daytime Sleepinesshttps://practicalneurology.com/news/httpswwwfdagovdrugsdefaulthtm/2468797/The Food and Drug Administration (FDA) has approved solriamfetol (Sunosi; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults with excessive daytime sleepiness (EDS)associated with narcolepsy or obstructive sleep apnea (OSA). Solriamfetol is a dual dopamine and norepinephrine reupt
- New CPT Code for Electrocorticography From Responsive Neurostimulatorhttps://practicalneurology.com/news/new-cpt-code-for-electrocorticography-from-responsive-neurostimulator/2468834/The American Medical Association (AMA) has issued a new Category/Current Procedural Terminology (CPT) code for electrocorticography from an implanted brain neurostimulator. The code applies to services that physicians perform with a responsive neurostimulator (RNS System; NeuroPace, Mountain
- New Drug Application Submitted for Low-Dose Fenfluramine for Treatment of Dravet Syndromehttps://practicalneurology.com/news/new-drug-application-submitted-for-low-dose-fenfluramine-for-treatment-of-dravet-syndrome/2468849/A new drug application (NDA) has been submitted to the Food and Drug Administration (FDA) for low-dose fenfluramine (Fintepla, previously known as ZX008; Zogenix, Emeryville, CA) for the treatment of seizures associated with Dravet syndrome. The NDA is based on data from 2 phase 3 clinical trials
- Practical Neurology Nominated as Finalist for 2 Eddie & Ozzie Awardshttps://practicalneurology.com/news/practical-neurology-nominated-as-finalist-for-2-eddie-ozzie-awards/2470285/Practical Neurology has been named a finalist for 2 categories in the 2023 Folio: Eddie & Ozzie Awards, a prestigious recognition program organized by Folio, a magazine industry–focused publication. Eddies are awarded on the basis of editorial excellence in publication
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Ted Pigeon, Editor-in-Chiefhttps://practicalneurology.com/profiles/ted-pigeon-editor-in-chief/OKA8zb/